Aggressive lobbying keeps seniors on Lucentis, prevents Medicare savings, USA TODAY article states
By
Tim Mullaney
Apr 28, 2014
Lobbying efforts have ensured that long-term care residents and other seniors are commonly prescribed the expensive drug Lucentis, even though the less costly drug Avastin has proven equally effective,...
Protective gene mutation gives hope to Alzheimer’s drug development
By
McKnight's Staff
Jul 16, 2012
Alzheimer’s researchers got a huge boost last week with the publication of a study showing that a rare genetic mutation prevents the buildup of beta amyloid in the brain.
Avastin more likely to cause blindness than Lucentis, study reports
By
McKnight's Staff
Jun 19, 2012
The cheaper of the two rival macular degeneration treatments could lead to blindness or other adverse events, new research determined.
Group recommends coordinating care for dual-eligibles, leaving more up to states
Jan 12, 2012
In order to promote coordination between Medicare and Medicaid services and to save money, the federal government and states should create an integrated care model for dual-eligible beneficiaries, a new...
FDA approves new macular degeneration treatment
Nov 22, 2011
The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision...
Macular degeneration treatment linked to blindness, FDA advisory says
Sep 06, 2011
Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.